Cargando…

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence

PURPOSE: To analyse outcomes of innovator ranibizumab (IRM) (Lucentis) and biosimilar ranibizumab (BRM) (Razumab) in Indian eyes with neovascular age-related macular degeneration (nAMD). METHODS: Retrospective observational study in nAMD patients, who were treated with IRM or BRM (3 loading doses fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakraborty, Debdulal, Mondal, Soumen, Boral, Subhendu, Das, Arnab, Sinha, Tushar Kanti, Majumdar, Saptorshi, Bhattacharya, Ranabir, Maitra, Ritobroto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097398/ https://www.ncbi.nlm.nih.gov/pubmed/37064960 http://dx.doi.org/10.2147/OPTH.S407219

Ejemplares similares

Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Ultra-widefield image of a toxocara granuloma with an adjacent retinal break and retinal detachment
por: Chakraborty, Debdulal, et al.
Publicado: (2019)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Role of intravitreal brolucizumab with intravitreal rtPA and pneumatic displacement for submacular hemorrhage: A case series
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Long-term clinical outcomes of submacular blood removal with isolated autologous retinal pigment epithelium-choroid patch graft transplantation in long-standing large-sized submacular hematomas: An Indian experience
por: Boral, Subhendu Kumar, et al.
Publicado: (2020)

Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Real-world outcomes and complications of different surgical approaches for significant submacular haemorrhages
por: Boral, Subhendu Kumar, et al.
Publicado: (2023)

THERMINATOR: THERMal heavy-IoN generATOR
por: Kisiel, A, et al.
Publicado: (2005)

Anatomical and functional outcomes one year after vitrectomy and retinal massage for large macular holes
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Response to comment on: Anatomical and functional outcomes one year after vitrectomy and retinal massage for large macular holes
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Response to comment on: Anatomical and functional outcomes one year after vitrectomy and retinal massage for large macular holes
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

A novel standardized reproducible method to calculate the area of internal limiting membrane peeled intra-operatively in macular hole surgery by using a video overlay—A long-term study in cases of idiopathic macular holes
por: Boral, Subhendu K, et al.
Publicado: (2020)

GladiaTOX: GLobal Assessment of Dose-IndicAtor in TOXicology
por: Belcastro, Vincenzo, et al.
Publicado: (2019)

Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study
por: Chakraborty, Debdulal, et al.
Publicado: (2023)

THERMINATOR 2: THERMal heavy IoN generATOR 2
por: Chojnacki, Mikolaj, et al.
Publicado: (2011)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity
por: Prajapati, Vipul, et al.
Publicado: (2023)

SIMPLE: Sparse Interaction Model over Peaks of moLEcules for fast, interpretable metabolite identification from tandem mass spectra
por: Nguyen, Dai Hai, et al.
Publicado: (2018)

Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis(®) (Ranibizumab) Biosimilar
por: Kim, Eunji, et al.
Publicado: (2022)

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
por: Soman, Manoj, et al.
Publicado: (2022)

Outro Ator no Aumento da Circulação Colateral no Coração – Outro Potencial Alvo Terapêutico na Medicina Cardiovascular?
por: Gowdak, Luis Henrique Wolff
Publicado: (2022)

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
por: Woo, Se Joon, et al.
Publicado: (2020)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
por: Apsangikar, Prasad, et al.
Publicado: (2021)

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment
por: Hatamnejad, Amin, et al.
Publicado: (2023)

Development and optimization of a self-microemulsifying drug delivery system for ator vastatin calcium by using d-optimal mixture design
por: Yeom, Dong Woo, et al.
Publicado: (2015)

Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
por: Verma, Lalit, et al.
Publicado: (2021)

The efficacy of Cognitive training in patients with VAsCular Cognitive Impairment, No dEmentia (the Cog-VACCINE study): study protocol for a randomized controlled trial
por: Tang, Yi, et al.
Publicado: (2016)

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
por: Kvarnhammar, Anne Månsson, et al.
Publicado: (2019)

Modified posterior drainage of post-operative suprachoroidal hemorrhage
por: Boral, Subhendu Kumar, et al.
Publicado: (2021)

Unfolding falciform folds and their consequences - To touch or not to touch
por: Boral, Subhendu Kumar, et al.
Publicado: (2022)

Commentary: Retinal detachment in eyes treated with Aurolab aqueous drainage implant for refractory glaucoma - Incidence and outcomes
por: Boral, Subhendu Kumar, et al.
Publicado: (2022)

Variable clinical profile of foveal hypoplasia in albinism
por: Kumar, Kshitiz, et al.
Publicado: (2020)

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes
por: Bressler, Neil M, et al.
Publicado: (2023)

Commentary: Indistinct retinal outer layers in the walls of idiopathic full thickness macular hole - A potential predictive biomarker for surgical outcomes
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Commentary: To evaluate the functional and anatomical outcomes for autologous retinal autograft with Finesse™ Flex Loop for failed macular holes
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kc5ef9i9duqvfnraam121a660h